(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Remain Fit and Sound with These Exercise Fundamentals - 2Israeli tourist data from 2025 misrepresented as mass exodus to Thailand
- 3NASA, in a rare move, cuts space station mission short after an astronaut's medical issue
- 4Health officials report 14 Legionnaires' disease cases in Florida, gym connection suspected
- 5What's your biological age? Experts explain the benefits and risks of at-home tests
- UN panel says Israel operating 'de facto policy of torture'
- Extraordinary Miracles: The Cherished Islands for a Tropical Get-away
- Instructions to Keep up with Your Traded Teeth for Life span
- Turning into a Sharp Financial backer: Individual budget Wins
- Malaysia To Revive Search for Missing Flight MH370
- Top 20 Wellbeing and Wellness Applications for a Sound Way of life
- Vote in favor of your #1 Kind of Cap
- The Force of Care: Living with Goal
- Innovative Versatility: Examples of overcoming adversity from Entrepreneurs
